背景:下一代激素疗法与循环肿瘤细胞(CTC)在前列腺切除术后生化复发中的相关性尚未阐明。
目的:为了评估醋酸阿比特龙联合强的松(AAP),前列腺床放射治疗(PBRT),和戈舍瑞林在前列腺切除术后生化复发的男性中,并研究CTC的效用。
方法:在这项单臂多中心2期试验中,在2012年12月至2019年1月之间招募了46名生化复发男性。中位随访时间为47个月。
方法:所有患者每天接受AAP1000mg(但PBRT期间为750mg),打捞PBRT,还有戈舍瑞林.
方法:当前列腺特异性抗原(PSA)水平≥0.2ng/ml时,主要结局是3年生化无复发生存期(bRFS)。次要结果包括PSA水平≥0.5ng/ml时的替代bRFS(alt-bRFS)和安全性评估。评估了CTC计数。
结论:3年bRFS和alt-bRFS分别为81.5%(95%置信区间orCI[66.4-90.3%])和95.6%(95%CI[83.5-98.9%]),分别。最常见的急性放疗相关不良反应(AE;所有级别均为尿频(41.3%)。最常见的晚期AE(所有级别)是尿失禁(15.2%)。3-4级急性或晚期放疗相关的AE很少。与放疗无关的最常见的不良事件是潮热(76%),高血压(63%),和肝细胞溶解(50%,其中20%为3-4级)。在患者中,11%的CTC计数≥5,这与较差的bRFS(p=0.042)和alt-bRFS(p=0.008)相关。CTC计数与较高复发率之间的关联与基线PSA水平和PSA倍增时间无关(分别为p=0.42和p=0.09)。这项研究是非随机的,患者数量有限,报告的临床事件很少。
结论:在抢救放射治疗中加入AAP和戈舍瑞林导致高bRFS和alt-bRFS。AE保持可控,尽管建议进行密切的肝脏监测。CTC计数似乎是预后和预测治疗反应的有希望的生物标志物。
结果:我们的研究是一项2期临床试验,显示了一种新型雄激素受体靶向剂(醋酸阿比特龙+泼尼松)在前列腺癌患者中的疗效和耐受性根治性前列腺切除术后前列腺特异性抗原升高,联合前列腺床放疗。结果还表明了循环肿瘤细胞检测的可行性和潜在价值。这构成了治疗前列腺癌的一个可能的进步。
BACKGROUND: The relevance of next-generation hormone therapies and circulating tumor cells (CTCs) are not elucidated in biochemical recurrence after prostatectomy.
OBJECTIVE: To evaluate the combination of abiraterone acetate plus prednisone (AAP), prostate bed radiotherapy (PBRT), and goserelin in biochemically relapsing men after prostatectomy, and to investigate the utility of CTCs.
METHODS: In this single-arm multicenter phase 2
trial, 46 biochemically relapsing men were enrolled between December 2012 and January 2019. The median follow-up was 47 mo.
METHODS: All patients received AAP 1000 mg daily (but 750 mg during PBRT), salvage PBRT, and goserelin.
METHODS: The primary outcome was 3-yr biochemical recurrence-free survival (bRFS) when prostate-specific antigen (PSA) levels were ≥0.2 ng/ml. The secondary outcomes included alternative bRFS (alt-bRFS) when PSA levels were ≥0.5 ng/ml and safety assessment. CTC count was assessed.
CONCLUSIONS: The 3-yr bRFS and alt-bRFS were 81.5% (95% confidence interval or CI [66.4-90.3%]) and 95.6% (95% CI [83.5-98.9%]), respectively. The most common acute radiotherapy-related adverse effect (AE; all grades was pollakiuria (41.3%). The most common late AE (all grades) was urinary incontinence (15.2%). Grade 3-4 acute or late radiotherapy-related AEs were scarce. Most frequent AEs nonrelated to radiotherapy were hot flashes (76%), hypertension (63%), and hepatic cytolysis (50%, of which 20% were of grades 3-4). Of the patients, 11% had a CTC count of ≥5, which was correlated with poorer bRFS (p = 0.042) and alt-bRFS (p = 0.008). The association between CTC count and higher rates of relapse was independent of the baseline PSA level and PSA doubling time (p = 0.42 and p = 0.09, respectively). This
study was nonrandomized with a limited number of patients, and few clinical events were reported.
CONCLUSIONS: Adding AAP to salvage radiation therapy and goserelin resulted in high bRFS and alt-bRFS. AEs remained manageable, although a close liver surveillance is advised. CTC count appears as a promising biomarker for prognosis and predicting response to treatment.
RESULTS: Our
study was a phase 2 clinical
trial that exhibited the efficacy and tolerance of a novel androgen-receptor targeting agent (abiraterone acetate plus prednisone) in patients with prostate cancer who experienced rising prostate-specific antigen after radical prostatectomy, in combination with prostate bed radiotherapy. The results also indicated the feasibility and potential value of circulating tumor cell detection, which constitutes a possible advance in managing prostate cancers.